80 related articles for article (PubMed ID: 21684455)
1. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin.
Nutt D; Goodwin G
Eur Neuropsychopharmacol; 2011 Jul; 21(7):495-9. PubMed ID: 21684455
[No Abstract] [Full Text] [Related]
2. Reductionism and proxy failure: From neuroscience to target-based drug discovery.
Sadri A; Paknezhad S
Behav Brain Sci; 2024 May; 47():e83. PubMed ID: 38738353
[TBL] [Abstract][Full Text] [Related]
3. Psychedelics in the treatment of unipolar and bipolar depression.
Bosch OG; Halm S; Seifritz E
Int J Bipolar Disord; 2022 Jul; 10(1):18. PubMed ID: 35788817
[TBL] [Abstract][Full Text] [Related]
4. Placebo Response and Its Predictors in Attention Deficit Hyperactivity Disorder: A Meta-Analysis and Comparison of Meta-Regression and MetaForest.
Castells X; Saez M; Barcheni M; Cunill R; Serrano D; López B; van Lissa CJ
Int J Neuropsychopharmacol; 2022 Jan; 25(1):26-35. PubMed ID: 34355753
[TBL] [Abstract][Full Text] [Related]
5. "Novel Psychopharmacology for Depressive Disorders".
Fornaro M; De Berardis D; Anastasia A; Fusco A
Adv Exp Med Biol; 2021; 1305():449-461. PubMed ID: 33834412
[TBL] [Abstract][Full Text] [Related]
6. Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences.
Grillon C; Robinson OJ; Cornwell B; Ernst M
Neuropsychopharmacology; 2019 Nov; 44(12):1999-2010. PubMed ID: 31226707
[TBL] [Abstract][Full Text] [Related]
7. When All Else Fails, Listen to the Patient: A Viewpoint on the Use of Ecological Momentary Assessment in Clinical Trials.
Mofsen AM; Rodebaugh TL; Nicol GE; Depp CA; Miller JP; Lenze EJ
JMIR Ment Health; 2019 Apr; 6(5):e11845. PubMed ID: 31066701
[TBL] [Abstract][Full Text] [Related]
8. A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial.
Trivedi MH; South C; Jha MK; Rush AJ; Cao J; Kurian B; Phillips M; Pizzagalli DA; Trombello JM; Oquendo MA; Cooper C; Dillon DG; Webb C; Grannemann BD; Bruder G; McGrath PJ; Parsey R; Weissman M; Fava M
Psychother Psychosom; 2018; 87(5):285-295. PubMed ID: 30110685
[TBL] [Abstract][Full Text] [Related]
9. How Realistic Are the Scientific Assumptions of the Neuroenhancement Debate? Assessing the Pharmacological Optimism and Neuroenhancement Prevalence Hypotheses.
Schleim S; Quednow BB
Front Pharmacol; 2018; 9():3. PubMed ID: 29403383
[TBL] [Abstract][Full Text] [Related]
10. From neuroscience to evidence based psychological treatments - The promise and the challenge, ECNP March 2016, Nice, France.
Goodwin GM; Holmes EA; Andersson E; Browning M; Jones A; Lass-Hennemann J; Månsson KN; Moessnang C; Salemink E; Sanchez A; van Zutphen L; Visser RM
Eur Neuropsychopharmacol; 2018 Feb; 28(2):317-333. PubMed ID: 29371024
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery in overcoming the blood-brain barrier: role of nasal mucosal grafting.
Marianecci C; Rinaldi F; Hanieh PN; Di Marzio L; Paolino D; Carafa M
Drug Des Devel Ther; 2017; 11():325-335. PubMed ID: 28184152
[TBL] [Abstract][Full Text] [Related]
12. Innovative approaches to bipolar disorder and its treatment.
Harrison PJ; Cipriani A; Harmer CJ; Nobre AC; Saunders K; Goodwin GM; Geddes JR
Ann N Y Acad Sci; 2016 Feb; 1366(1):76-89. PubMed ID: 27111134
[TBL] [Abstract][Full Text] [Related]
13. Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.
Peciña M; Bohnert AS; Sikora M; Avery ET; Langenecker SA; Mickey BJ; Zubieta JK
JAMA Psychiatry; 2015 Nov; 72(11):1087-94. PubMed ID: 26421634
[TBL] [Abstract][Full Text] [Related]
14. Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism.
Cipriani A; Geddes JR
BMC Med; 2014 Jun; 12():105. PubMed ID: 24962638
[TBL] [Abstract][Full Text] [Related]
15. T-type calcium channel blockers as neuroprotective agents.
Kopecky BJ; Liang R; Bao J
Pflugers Arch; 2014 Apr; 466(4):757-65. PubMed ID: 24563219
[TBL] [Abstract][Full Text] [Related]
16. Modeling intracellular signaling underlying striatal function in health and disease.
Nair AG; Gutierrez-Arenas O; Eriksson O; Jauhiainen A; Blackwell KT; Kotaleski JH
Prog Mol Biol Transl Sci; 2014; 123():277-304. PubMed ID: 24560149
[TBL] [Abstract][Full Text] [Related]
17. ROAMER: roadmap for mental health research in Europe.
Haro JM; Ayuso-Mateos JL; Bitter I; Demotes-Mainard J; Leboyer M; Lewis SW; Linszen D; Maj M; McDaid D; Meyer-Lindenberg A; Robbins TW; Schumann G; Thornicroft G; Van Der Feltz-Cornelis C; Van Os J; Wahlbeck K; Wittchen HU; Wykes T; Arango C; Bickenbach J; Brunn M; Cammarata P; Chevreul K; Evans-Lacko S; Finocchiaro C; Fiorillo A; Forsman AK; Hazo JB; Knappe S; Kuepper R; Luciano M; Miret M; Obradors-Tarragó C; Pagano G; Papp S; Walker-Tilley T
Int J Methods Psychiatr Res; 2014 Jan; 23 Suppl 1(Suppl 1):1-14. PubMed ID: 24375532
[TBL] [Abstract][Full Text] [Related]
18. Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome.
Rutherford BR; Tandler J; Brown PJ; Sneed JR; Roose SP
Am J Geriatr Psychiatry; 2014 Dec; 22(12):1452-61. PubMed ID: 24200597
[TBL] [Abstract][Full Text] [Related]
19. Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.
Sugarman P; Mitchell A; Frogley C; Dickens GL; Picchioni M
Ther Adv Psychopharmacol; 2013 Aug; 3(4):233-43. PubMed ID: 24167695
[TBL] [Abstract][Full Text] [Related]
20. The size, burden and cost of disorders of the brain in the UK.
Fineberg NA; Haddad PM; Carpenter L; Gannon B; Sharpe R; Young AH; Joyce E; Rowe J; Wellsted D; Nutt DJ; Sahakian BJ
J Psychopharmacol; 2013 Sep; 27(9):761-70. PubMed ID: 23884863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
